Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CELIAC DISEASE, SUSCEPTIBILITY TO, 3 (finding)
|
1 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.700 | 0 | ||||||||
HASHIMOTO THYROIDITIS, SUSCEPTIBILITY TO
|
1 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.700 | 0 | ||||||||
Autoantibody measurement
|
52 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.700 | 1.000 | 1 | 2011 | 2011 | |||||
AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 1
|
142 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 2
|
132 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
AUTOIMMUNE DISEASE, SUSCEPTIBILITY TO, 6
|
141 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
Immune System Diseases
|
116 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.700 | 1.000 | 1 | 2011 | 2011 | |||||
Multiple Sclerosis
|
1022 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.700 | 1.000 | 1 | 2011 | 2011 | |||||
Allergic rhinitis (disorder)
|
176 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Ankylosing spondylitis
|
609 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Appendicitis
|
10 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2020 | 2020 | |||||
Breast Carcinoma
|
2793 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Childhood Osteosarcoma
|
151 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Chronic kidney disease stage 5
|
194 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Colorectal Carcinoma
|
1962 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Cytomegalovirus Infections
|
26 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Drug-Induced Liver Disease
|
29 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Ewings sarcoma
|
25 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Fatigue
|
67 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Giant Cell Arteritis
|
78 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Hashimoto Disease
|
131 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Hepatitis C
|
347 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Inflammatory Bowel Diseases
|
605 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2010 | 2010 | |||||
Kidney Failure, Chronic
|
425 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Liver carcinoma
|
942 | 0.623 | 0.720 | 2 | 203874196 | downstream gene variant | G/A | snv | 0.37 | 0.010 | 1.000 | 1 | 2019 | 2019 |